<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32418425</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-3907</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Journal of proteome research</Title><ISOAbbreviation>J Proteome Res</ISOAbbreviation></Journal><ArticleTitle>Metabolite Profiling Reveals Predictive Biomarkers and the Absence of &#x3b2;-Methyl Amino-l-alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>3276</StartPage><EndPage>3285</EndPage><MedlinePgn>3276-3285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jproteome.0c00216</ELocationID><Abstract><AbstractText>By employing chip-based capillary zone electrophoresis coupled to high-resolution mass spectrometry, we profiled the plasma metabolome of 134 patients diagnosed with sporadic amyotrophic lateral sclerosis (ALS) (81 males and 53 females) and 118 individuals deemed healthy (49 males and 69 females). The most significant markers (<i>p</i> &lt; 0.01) were creatine, which was 49% elevated, and creatinine and methylhistidine, which were decreased by 20 and 24%, respectively, in ALS patients. The ratio of creatine versus creatinine increased 370 and 200% for male and female ALS patients, respectively. In addition, male ALS patients on an average had 5-13% lower amounts of seven essential amino acids, whereas females did not significantly differ from healthy controls. We developed two models using the metabolite abundances: (1) a classification model for the separation of ALS and healthy samples and (2) a classification model for the prediction of disease progression based on the ALS functional rating score. Utilizing a Monte Carlo cross-validation approach, a linear discriminant analysis model achieved a mean area under the receiver operating characteristic curve (AUC) of 0.85 (0.06) with a mean sensitivity of 80% (9%) and specificity of 78% (10%) for the separation of ALS and controls, respectively. A support vector machine classifier predicted progression categories with an AUC of 0.90 (0.06) with a mean sensitivity of 73% (10%) and a specificity of 86% (5%). Lastly, using a previously reported assay with a stable isotope-labeled (<sup>13</sup>C<sub>3</sub><sup>15</sup>N<sub>2</sub>) spike-in standard, we were unable to detect the exogenous neurotoxic metabolite, &#x3b2;-methylamino-l-alanine, in the free or protein-bound fraction of any of the 252 plasma samples.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bereman</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-2722-064X</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Health and the Environment, North Carolina State University, Raleigh, North Carolina 27695, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>Kaylie I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabaretnam</LastName><ForeName>Tharani</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Centre for MND Research Faculty of Medicine, Health and Human Sciences Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furlong</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Centre for MND Research Faculty of Medicine, Health and Human Sciences Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Dominic B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>The Centre for MND Research Faculty of Medicine, Health and Human Sciences Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillemin</LastName><ForeName>Gilles J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>The Centre for MND Research Faculty of Medicine, Health and Human Sciences Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellinger</LastName><ForeName>Allyson L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muddiman</LastName><ForeName>David C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0003-2216-499X</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Health and the Environment, North Carolina State University, Raleigh, North Carolina 27695, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Education, Technology and Research Innovation Center, North Carolina State University, Raleigh, North Carolina 27695, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Proteome Res</MedlineTA><NlmUniqueID>101128775</NlmUniqueID><ISSNLinking>1535-3893</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BMAA</Keyword><Keyword MajorTopicYN="N">CZE-MS/MS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">metabolites</Keyword><Keyword MajorTopicYN="N">plasma</Keyword></KeywordList><CoiStatement>COMPETING INTERESTS. The Authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32418425</ArticleId><ArticleId IdType="mid">NIHMS1611259</ArticleId><ArticleId IdType="pmc">PMC8273918</ArticleId><ArticleId IdType="doi">10.1021/acs.jproteome.0c00216</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zarei S; Carr K; Reiley L; Diaz K; Guerra O; Altamirano PF; Pagani W; Lodin D; Orozco G; Chinea A A Comprehensive Review of Amyotrophic Lateral Sclerosis. Surg. Neurol. Int 2015, 6, 171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S; Murn M; Choi PJ Respiratory Failure in Amyotrophic Lateral Sclerosis. Chest 2019, 155 (2), 401&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyotrophic Lateral Sclerosis/Riluzole Study Group II; Lacomblez L; Bensimon G; Meininger V; Leigh PN; Guillet P Dose-Ranging Study of Riluzole in Amyotrophic Lateral Sclerosis. Lancet 1996, 347 (9013), 1425&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C; Heiman-Patterson T; Kittrell P; Baranovsky T; McAnanama G; Bower L; Agnese W; Martin M Radicava (edaravone) for Amyotrophic Lateral Sclerosis: US Experience at 1 Year after Launch. Amyotroph. Lateral Scler. Frontotemporal Degener 2019, 20 (7&#x2013;8), 605&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">31364409</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz MP Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis. P T 2018, 43 (1), 25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737249</ArticleId><ArticleId IdType="pubmed">29290672</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D; Mansfield C; Moussy A; Hermine O ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci 2017, 9, 68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR; Miller RG; Swash M; Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial Revisited: Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord 2000, 1 (5), 293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S; Macklin EA; Lee A; Murphy A; Chang J; Zipf A; Cudkowicz M; Atassi N Diagnostic Timelines and Delays in Diagnosing Amyotrophic Lateral Sclerosis (ALS). Amyotroph. Lateral Scler. Frontotemporal Degener 2014, 15 (5&#x2013;6), 453&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of Activities of Daily Living in Patients with Amyotrophic Lateral Sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. Arch. Neurol 1996, 53 (2), 141&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">8639063</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel DB Factors Associated with Clinical Trials That Fail and Opportunities for Improving the Likelihood of Success: A Review. Contemp Clin Trials Commun 2018, 11, 156&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092479</ArticleId><ArticleId IdType="pubmed">30112460</ArticleId></ArticleIdList></Reference><Reference><Citation>Taga A; Maragakis NJ Current and Emerging ALS Biomarkers: Utility and Potential in Clinical Trials. Expert Rev. Neurother 2018, 18 (11), 871&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">30273061</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu LT; Bowser R Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics 2017, 14 (1), 119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233638</ArticleId><ArticleId IdType="pubmed">27933485</ArticleId></ArticleIdList></Reference><Reference><Citation>Joilin G; Leigh PN; Newbury SF; Hafezparast M An Overview of MicroRNAs as Biomarkers of ALS. Front. Neurol 2019, 10, 186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416171</ArticleId><ArticleId IdType="pubmed">30899244</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K; Van Damme P Diagnostic and Prognostic Performance of Neurofilaments in ALS. Front. Neurol 2018, 9, 1167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J; Petzold A; S&#xfc;ssmuth SD; Ludolph AC; Tumani H Axonal Damage Markers in Cerebrospinal Fluid Are Increased in ALS. Neurology 2006, 66 (6), 852&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijn TS; Abdo WF; Schelhaas HJ; Verbeek MM CSF Neurofilament Protein Analysis in the Differential Diagnosis of ALS. J. Neurol 2009, 256 (4), 615&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">19296046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J; An J; Bowser R; Andersen PM; Shaw CE pNfH Is a Promising Biomarker for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener 2013, 14 (2), 146&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">23134506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant HC Dephosphorylation of Neurofilament Proteins Enhances Their Susceptibility to Degradation by Calpain. Biochem. J 1988, 256 (2), 665&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1135461</ArticleId><ArticleId IdType="pubmed">2851997</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein ME; Sternberger NH; Sternberger LA Phosphorylation Protects Neurofilaments against Proteolysis. J. Neuroimmunol 1987, 14 (2), 149&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">3029175</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P; Feneberg E; Weishaupt J; Brettschneider J; Tumani H; Andersen PM; von Arnim CAF; B&#xf6;hm S; Kassubek J; Kubisch C; Lul&#xe9; D; M&#xfc;ller H-P; Muche R; Pinkhardt E; Oeckl P; Rosenbohm A; Anderl-Straub S; Volk AE; Weydt P; Ludolph AC; Otto M Neurofilaments in the Diagnosis of Motoneuron Diseases: A Prospective Study on 455 Patients. J. Neurol. Neurosurg. Psychiatry 2016, 87 (1), 12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A Neurofilament Light Chain: A Prognostic Biomarker in Amyotrophic Lateral Sclerosis. Neurology 2015, 84 (22), 2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereman MS; Beri J; Enders JR; Nash T Machine Learning Reveals Protein Signatures in CSF and Plasma Fluids of Clinical Value for ALS. Sci. Rep 2018, 8 (1), 16334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6218542</ArticleId><ArticleId IdType="pubmed">30397248</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldacci F; Lista S; Palermo G; Giorgi FS; Vergallo A; Hampel H The Neuroinflammatory Biomarker YKL-40 for Neurodegenerative Diseases: Advances in Development. Expert Rev. Proteomics 2019, 16 (7), 593&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">31195846</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG; Gray E; Bampton A; Raciborska D; Talbot K; Turner MR CSF Chitinase Proteins in Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry 2019, 90 (11), 1215&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera TW; Borges K Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments. Front. Neurosci 2016, 10, 611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5222822</ArticleId><ArticleId IdType="pubmed">28119559</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry TL; Krieger C; Hansen S; Eisen A Amyotrophic Lateral Sclerosis: Amino Acid Levels in Plasma and Cerebrospinal Fluid. Ann. Neurol 1990, 28 (1), 12&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375629</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD; Tsai G; Kuncl RW; Clawson L; Cornblath DR; Drachman DB; Pestronk A; Stauch BL; Coyle JT Abnormal Excitatory Amino Acid Metabolism in Amyotrophic Lateral Sclerosis. Ann. Neurol 1990, 28 (1), 18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375630</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreux-Varoquaux O; Bensimon G; Lacomblez L; Salachas F; Pradat PF; Le Forestier N; Marouan A; Dib M; Meininger V Glutamate Levels in Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis: A Reappraisal Using a New HPLC Method with Coulometric Detection in a Large Cohort of Patients. J. Neurol. Sci 2002, 193 (2), 73&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790386</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A; Moritz T; Marklund SL; Antti H; Andersen PM Disease-Related Changes in the Cerebrospinal Fluid Metabolome in Amyotrophic Lateral Sclerosis Detected by GC/TOFMS. PLoS One 2011, 6 (4), e17947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070699</ArticleId><ArticleId IdType="pubmed">21483737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A; Jonsson P; Ahnlund M; Antti H; Marklund SL; Moritz T; Forsgren L; Andersen PM; Trupp M Multi-Platform Mass Spectrometry Analysis of the CSF and Plasma Metabolomes of Rigorously Matched Amyotrophic Lateral Sclerosis, Parkinson&#x2019;s Disease and Control Subjects. Mol. Biosyst 2016, 12 (4), 1287&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">26883206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA; Brown MV; Alexander D; Li Z; Wulff JE; Lawson R; Jaffa M; Milburn MV; Ryals JA; Bowser R; Cudkowicz ME; Berry JD; Northeast ALS Consortium. Plasma Metabolomic Biomarker Panel to Distinguish Patients with Amyotrophic Lateral Sclerosis from Disease Mimics. Amyotroph. Lateral Scler. Frontotemporal Degener 2014, 15 (5&#x2013;6), 362&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG; Mash DC Beyond Guam: The cyanobacteria/BMAA Hypothesis of the Cause of ALS and Other Neurodegenerative Diseases. Amyotroph. Lateral Scler 2009, 10 Suppl 2, 7&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19929726</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamczyk M; Gebler JC; Wu J Identification of Phosphopeptides by Chemical Modification with an Isotopic Tag and Ion Trap Mass Spectrometry. Rapid Commun. Mass Spectrom 2002, 16 (10), 999&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">11968134</ArticleId></ArticleIdList></Reference><Reference><Citation>Beri J; Kirkwood KI; Muddiman DC; Bereman MS A Novel Integrated Strategy for the Detection and Quantification of the Neurotoxin &#x3b2;-N-Methylamino-L-Alanine in Environmental Samples. Anal. Bioanal. Chem 2018, 410 (10), 2597&#x2013;2605.</Citation><ArticleIdList><ArticleId IdType="pubmed">29455280</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams KJ; Pratt B; Bose N; Dubois LG; St John-Williams L; Perrott KM; Ky K; Kapahi P; Sharma V; MacCoss MJ; Moseley MA; Colton CA; MacLean BX; Schilling B; Thompson JW; Alzheimer&#x2019;s Disease Metabolomics Consortium. Skyline for Small Molecules: A Unifying Software Package for Quantitative Metabolomics. J. Proteome Res 2020, 19 (4), 1447&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127945</ArticleId><ArticleId IdType="pubmed">31984744</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling B; Rardin MJ; MacLean BX; Zawadzka AM; Frewen BE; Cusack MP; Sorensen DJ; Bereman MS; Jing E; Wu CC; Verdin E; Kahn CR; Maccoss MJ; Gibson BW Platform-Independent and Label-Free Quantitation of Proteomic Data Using MS1 Extracted Ion Chromatograms in Skyline: Application to Protein Acetylation and Phosphorylation. Mol. Cell. Proteomics 2012, 11 (5), 202&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418851</ArticleId><ArticleId IdType="pubmed">22454539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V; Eckels J; Taylor GK; Shulman NJ; Stergachis AB; Joyner SA; Yan P; Whiteaker JR; Halusa GN; Schilling B; Gibson BW; Colangelo CM; Paulovich AG; Carr SA; Jaffe JD; MacCoss MJ; MacLean B Panorama: A Targeted Proteomics Knowledge Base. J. Proteome Res 2014, 13 (9), 4205&#x2013;4210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4156235</ArticleId><ArticleId IdType="pubmed">25102069</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y; Hochberg Y Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Series B Stat. Methodol 1995, 57 (1), 289&#x2013;300.</Citation></Reference><Reference><Citation>Guyon I; Weston J; Barnhill S; Vapnik V Gene Selection for Cancer Classification Using Support Vector Machines. Mach. Learn 2002, 46 (1), 389&#x2013;422.</Citation></Reference><Reference><Citation>Caputo B; Sim K; Furesjo F; Smola A Appearance-Based Object Recognition Using SVMs: Which Kernel Should I Use? 2001.</Citation></Reference><Reference><Citation>Hothorn T; Leisch F; Zeileis A; Hornik K The Design and Analysis of Benchmark Experiments. J. Comput. Graph. Stat 2005, 14 (3), 675&#x2013;699.</Citation></Reference><Reference><Citation>Chawla NV; Bowyer KW; Hall LO; Kegelmeyer WP SMOTE: Synthetic Minority Over-Sampling Technique. 1 2002, 16, 321&#x2013;357.</Citation></Reference><Reference><Citation>Harrington TM; Cohen MD; Bartleson JD; Ginsburg WW Elevation of Creatine Kinase in Amyotrophic Lateral Sclerosis. Arthritis &amp; Rheumatism 1983, 26 (2), 201&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">6824516</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq M; Lee E; Bradburn M; McDermott C; Shaw P ELEVATED CREATINE KINASE SUGGESTS BETTER PROGNOSIS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS. J. Neurol. Neurosurg. Psychiatry 2013, 84 (11), e2&#x2013;e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H; Cui L; Guan Y; Liu M; Li X; Shen D; Li D; Cui B; Fang J; Ding Q; Zhang K; Liu S Correlation of Creatine Kinase Levels with Clinical Features and Survival in Amyotrophic Lateral Sclerosis. Front. Neurol 2017, 8, 322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494475</ArticleId><ArticleId IdType="pubmed">28717355</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J; King RM; Jackson CE; Bedlack RS; Barohn RJ; Dick A; Phillips LH; Chapin J; Gelinas DF; Lou J-S Creatine Monohydrate in ALS: Effects on Strength, Fatigue, Respiratory Status and ALSFRS. Amyotroph. Lateral Scler 2008, 9 (5), 266&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631354</ArticleId><ArticleId IdType="pubmed">18608103</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi P; Ferrante RJ; Matthews RT; Bogdanov MB; Klein AM; Andreassen OA; Mueller G; Wermer M; Kaddurah-Daouk R; Beal MF Neuroprotective Effects of Creatine in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis. Nat. Med 1999, 5 (3), 347&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">10086395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J; Thornton JC; Pierson RN Urinary Excretion of Creatinine and 3-Methylhistidine for Estimation of Skeletal Muscle Mass in Humans: An Overview. In Quality of the Body Cell Mass; Springer; New York, 2000; pp 89&#x2013;94.</Citation></Reference><Reference><Citation>He F; Wu C; Li P; Li N; Zhang D; Zhu Q; Ren W; Peng Y Functions and Signaling Pathways of Amino Acids in Intestinal Inflammation. Biomed Res. Int 2018, 2018, 9171905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846438</ArticleId><ArticleId IdType="pubmed">29682569</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison D; Mehta P; van Es MA; Stommel E; Drory VE; Nefussy B; van den Berg LH; Crayle J; Bedlack R; Pooled Resource Open-Access ALS Clinical Trials Consortium. &#x201c;ALS Reversals&#x201d;: Demographics, Disease Characteristics, Treatments, and Co-Morbidities. Amyotroph. Lateral Scler. Frontotemporal Degener 2018, 19 (7&#x2013;8), 495&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">29607695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M Amyotrophic Lateral Sclerosis Mimic Syndromes. Iran J Neurol 2016, 15 (2), 85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4912674</ArticleId><ArticleId IdType="pubmed">27326363</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezzapesa DM; D&#x2019;Errico E; Tortelli R; Distaso E; Cortese R; Tursi M; Federico F; Zoccolella S; Logroscino G; Dicuonzo F; Simone IL Cortical Thinning and Clinical Heterogeneity in Amyotrophic Lateral Sclerosis. PLoS One 2013, 8 (11), e80748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835750</ArticleId><ArticleId IdType="pubmed">24278317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira GC; McKenna MC L-Carnitine and Acetyl-L-Carnitine Roles and Neuroprotection in Developing Brain. Neurochem. Res 2017, 42 (6), 1661&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5621476</ArticleId><ArticleId IdType="pubmed">28508995</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E; Pupillo E; Bonito V; Buzzi P; Caponnetto C; Chi&#xf2; A; Corbo M; Giannini F; Inghilleri M; Bella VL; Logroscino G; Lorusso L; Lunetta C; Mazzini L; Messina P; Mora G; Perini M; Quadrelli ML; Silani V; Simone IL; Tremolizzo L; Italian ALS Study Group. Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener 2013, 14 (5&#x2013;6), 397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernoff N; Hill DJ; Diggs DL; Faison BD; Francis BM; Lang JR; Larue MM; Le T-T; Loftin KA; Lugo JN; Schmid JE; Winnik WM A Critical Review of the Postulated Role of the Non-Essential Amino Acid, &#x3b2;-N-Methylamino-L-Alanine, in Neurodegenerative Disease in Humans. J. Toxicol. Environ. Health B Crit. Rev 2017, 20 (4), 1&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6503681</ArticleId><ArticleId IdType="pubmed">28598725</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan MW Beta-Methylamino-L-Alanine (BMAA) and Amyotrophic Lateral Sclerosis-Parkinsonism Dementia of the Western Pacific. Ann. N. Y. Acad. Sci 1992, 648, 161&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1637043</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan MW; Marini AM Debating the Cause of a Neurological Disorder. Science 2006, 313 (5794), 1737.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990532</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneely JP; Chevallier OP; Graham S; Greer B; Green BD; Elliott CT &#x3b2;-Methylamino-L-Alanine (BMAA) Is Not Found in the Brains of Patients with Confirmed Alzheimer&#x2019;s Disease. Sci. Rep 2016, 6, 36363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099567</ArticleId><ArticleId IdType="pubmed">27821863</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ; Li K; Perl DP; Galasko D Lack of Beta-Methylamino-L-Alanine in Brain from Controls, AD, or Chamorros with PDC. Neurology 2005, 65 (5), 768&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157919</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox PA; Davis DA; Mash DC; Metcalf JS; Banack SA Dietary Exposure to an Environmental Toxin Triggers Neurofibrillary Tangles and Amyloid Deposits in the Brain. Proc. Biol. Sci 2016, 283 (1823). 10.1098/rspb.2015.2397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rspb.2015.2397</ArticleId><ArticleId IdType="pmc">PMC4795023</ArticleId><ArticleId IdType="pubmed">26791617</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott LL; Downing TG A Single Neonatal Exposure to BMAA in a Rat Model Produces Neuropathology Consistent with Neurodegenerative Diseases. Toxins 2017, 10 (1). 10.3390/toxins10010022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins10010022</ArticleId><ArticleId IdType="pmc">PMC5793109</ArticleId><ArticleId IdType="pubmed">29286334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>